| miR-221 directly inhibits the expression of thyroid hormone receptor beta (THRB), an important tumor suppressor gene, and inhibits thyroid hormone-THRB pathway | thyroid, |
| Results showed that miR-221/222 cluster_s expression was down-regulated in castration-resistant prostate cancer cells (CPRC) and function as tumour suppressors. Also, low expression of miR-222 predicted a short duration of progression to CRPC. | prostate, |
| the tumor suppressive role of miR-221-3p in epithelial ovarian cancer | ovarian, |
| downregulation of miR-221 (3p and 5p) during prostate cancer progression suggests a suppressive role for miR-221. We report that miR-221-5p acts as tumor suppressor miRNA in prostate cancer cell line models and reduces tumor burden in mouse and zebrafish in vivo models. miR-221 was identified as key regulator of a network of other miRNAs in prostate cancer and has the potential to drastically modulate cell physiology. | prostate, |
| the tumor suppressive role of miR-221-3p in MB cell proliferation at least in part via targeting EIF5A2 | None |
| R-221/222 can be regarded as a new family of oncogenes, directly targeting the tumor suppressor p27(Kip1), and their overexpression might be contribute to the oncogenesis and progression of prostate carcinoma through p27(Kip1) down-regulation | prostate, |
| miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. | prostate, |
| MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. | liver, |
| The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice. | prostate, |
| Functional links between clustered microRNAs: suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer. | gastric, |
| miR-221 overexpression contributes to liver tumorigenesis. | liver, |
| A Variant in a MicroRNA complementary site in the 3 UTR of the KIT oncogene increases risk of acral melanoma. | skin, |
| miR-221/222 function as oncogenic microRNAs in human gliomas, at least in part, by targeting Cx43. | glioma, |
| overexpression of oncogenic miR-221 and miR-222 caused by HMGB1 is associated with an increase in malignancy scores of papillary thyroid cancer cells, namely cell growth and motility | thyroid, |
| Overexpression of primary microRNA 221/222 in acute myeloid leukemia. | leukemia, |
| miR-221/222 represents a novel molecular marker and putative oncogene in acute myeloid leukemia | leukemia, |
| Data show that miR-221 is an oncogenic miRNA which may regulate colorectal cancer (CRC) migration and invasion through targeting RECK. | colorectal, |
| Data indicate that overexpressed miR-221/222 may play an oncogenic role in pancreatic cancer by inducing the expression of MMP-2 and MMP-9, thus leading to cancer cell invasion. | pancreatic, |
| Suggest that miR-221 plays an oncogenic role in renal cancer cell proliferation, migration and invasion by directly inhibiting the tumor suppressor TIMP2. | kidney, |
| miR-221 is an oncogenic miRNA which promotes Capan-2 pancreatic ductal adenocarcinoma cells proliferation by targeting PTEN-Akt pathway. | pancreatic, |